Pfizer and BioNTech Pause COVID-19 Vaccine Trial Due to Low Enrollment

Pfizer and BioNTech have halted their substantial U.S. trial of the updated COVID-19 vaccine for adults aged 50 to 64, due to a lack of enrolment that prevents the collection of essential data. The companies informed the FDA of this decision, which is unrelated to any safety concerns.

The trial closures followed a review of epidemiological trends, highlighting a decrease in demand for COVID vaccine booster shots. The FDA had necessitated extensive, placebo-controlled trials in this demographic, but Pfizer and BioNTech struggled to enroll the target 25,000 to 30,000 participants.

Despite the challenges faced by Pfizer and BioNTech, Moderna continues a similar trial but with its own recruitment obstacles. COVID-19 vaccines maintain their importance, although U.S. booster uptake remains low. The lack of new trial data may affect future FDA recommendations for updated vaccine use in certain age groups.